Wall Street Zen Downgrades Autonomix Medical (NASDAQ:AMIX) to Strong Sell

Autonomix Medical (NASDAQ:AMIX) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

Several other analysts have also weighed in on the company. Zacks Research upgraded Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. Weiss Ratings raised Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Autonomix Medical has an average rating of “Hold” and an average target price of $42.00.

Autonomix Medical Stock Performance

AMIX stock opened at $5.32 on Friday. Autonomix Medical has a 52 week low of $2.44 and a 52 week high of $32.55. The company has a market capitalization of $5.16 million, a price-to-earnings ratio of -0.13 and a beta of -1.16. The firm’s 50-day moving average is $6.34 and its two-hundred day moving average is $7.55.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.40) by $1.38. On average, equities research analysts predict that Autonomix Medical will post -20.17 earnings per share for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.